# Flotetuzumab for Relapsed Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Following Allogeneic Hematopoietic Cell Transplantation (Allo-HCT)

> **NCT04582864** · PHASE2 · TERMINATED · sponsor: **Washington University School of Medicine** · enrollment: 11 (actual)

## Conditions studied

- Relapsed Acute Myeloid Leukemia

## Interventions

- **DRUG:** Flotetuzumab
- **PROCEDURE:** Donor lymphocyte infusion

## Key facts

- **NCT ID:** NCT04582864
- **Lead sponsor:** Washington University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-05-20
- **Primary completion:** 2024-03-29
- **Final completion:** 2024-07-26
- **Target enrollment:** 11 (ACTUAL)
- **Why stopped:** The sponsor is no longer supporting the drug
- **Last updated:** 2024-12-06

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04582864

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04582864, "Flotetuzumab for Relapsed Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Following Allogeneic Hematopoietic Cell Transplantation (Allo-HCT)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04582864. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*